Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms that are covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last year […]